PMID- 37277664
OWN - NLM
STAT- MEDLINE
DCOM- 20230801
LR  - 20240320
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Print)
IS  - 0012-186X (Linking)
VI  - 66
IP  - 9
DP  - 2023 Sep
TI  - What else can we do to prevent diabetic retinopathy?
PG  - 1614-1621
LID - 10.1007/s00125-023-05940-5 [doi]
AB  - The classical modifiable factors associated with the onset and progression of 
      diabetic retinopathy are the suboptimal control of blood glucose levels and 
      hypertension, as well as dyslipidaemia. However, there are other less recognised 
      modifiable factors that can play a relevant role, such as the presence of obesity 
      or the abnormal distribution of adipose tissue, and others related to lifestyle 
      such as the type of diet, vitamin intake, exercise, smoking and sunlight 
      exposure. In this article we revisit the prevention of diabetic retinopathy based 
      on modulating the modifiable risk factors, as well as commenting on the potential 
      impact of glucose-lowering drugs on the condition. The emerging concept that 
      neurodegeneration is an early event in the development of diabetic retinopathy 
      points to neuroprotection as a potential therapeutic strategy to prevent the 
      advanced stages of the disease. In this regard, the better phenotyping of very 
      early stages of diabetic retinopathy and the opportunity of arresting its 
      progression using treatments targeting the neurovascular unit (NVU) are 
      discussed.
CI  - (c) 2023. The Author(s).
FAU - Simo, Rafael
AU  - Simo R
AUID- ORCID: 0000-0003-0475-3096
AD  - Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain. 
      rafael.simo@vhir.org.
AD  - Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, 
      Barcelona, Spain. rafael.simo@vhir.org.
AD  - CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM, ID CB15/00071), 
      Instituto de Salud Carlos III (ISCIII), Madrid, Spain. rafael.simo@vhir.org.
FAU - Hernandez, Cristina
AU  - Hernandez C
AUID- ORCID: 0000-0002-3109-1721
AD  - Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.
AD  - Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, 
      Barcelona, Spain.
AD  - CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM, ID CB15/00071), 
      Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230606
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
MH  - Humans
MH  - *Diabetic Retinopathy
MH  - Risk Factors
MH  - *Hypertension/complications
MH  - Obesity/complications
MH  - Smoking
MH  - *Diabetes Mellitus
PMC - PMC10390367
OTO - NOTNLM
OT  - Diabetic retinopathy
OT  - Modifiable risk factors
OT  - Neurovascular unit
EDAT- 2023/06/06 01:11
MHDA- 2023/08/01 06:45
PMCR- 2023/06/06
CRDT- 2023/06/05 23:29
PHST- 2023/01/04 00:00 [received]
PHST- 2023/03/31 00:00 [accepted]
PHST- 2023/08/01 06:45 [medline]
PHST- 2023/06/06 01:11 [pubmed]
PHST- 2023/06/05 23:29 [entrez]
PHST- 2023/06/06 00:00 [pmc-release]
AID - 10.1007/s00125-023-05940-5 [pii]
AID - 5940 [pii]
AID - 10.1007/s00125-023-05940-5 [doi]
PST - ppublish
SO  - Diabetologia. 2023 Sep;66(9):1614-1621. doi: 10.1007/s00125-023-05940-5. Epub 
      2023 Jun 6.